AbstractWe are in the midst of a therapeutic revolution. An H1 report released by Alliance for Regenerative Medicine (ARM) highlights a record-breaking year, with over 1,320 ongoing clinical trials worldwide and 1000+ therapeutic developers. We are on track to expect the highest number of advanced therapy regulatory approvals during 2021, when compared to previous years.
This panel, sponsored by Precision ADVANCE, will feature insights from industry leaders on the current state of the CGTx sector, and the future of advanced medicines including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists will also discuss manufacturing and talent bottlenecks, and the evolution of reimbursement payment models.
Attendees will hear from industry experts about:
-Current state of the advanced medicines industry
-Continued investment in the advanced medicines sector
-New technologies, bottlenecks, and solutions
-The evolution of reimbursement payment models
-Anticipating regulatory hurdles and navigating political dynamics specific to cell and gene therapies